Tharimmune, Inc. (CNTN) compared with its closest peers (TNXP, ORMP, KRRO, NKTX, CUE). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | $200.38M | -1.1 |
| Oramed Pharmaceuticals Inc. (ORMP) | $199.67M | 3.9 |
| Korro Bio, Inc. (KRRO) | $193.49M | -0.6 |
| Nkarta, Inc. (NKTX) | $190.16M | -1.3 |
| Cue Biopharma, Inc. (CUE) | $174.06M | -1.1 |
| Lifecore Biomedical, Inc. (LFCR) | $172.61M | -15.2 |
| Indaptus Therapeutics, Inc. (INDP) | $170.55M | -0.1 |
| OnKure Therapeutics, Inc. (OKUR) | $158.95M | -0.7 |
| NRx Pharmaceuticals, Inc. (NRXP) | $152.83M | -2.0 |
| Assertio Holdings, Inc. (ASRT) | $151.83M | -1.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
CNTN overview · CNTN earnings · CNTN financials · CNTN KPIs · CNTN investor relations · CNTN ownership · CNTN filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.